Curis

Curis aims for phase 3 as FDA lifts final hold on leukemia med

The FDA has freed Curis from a remaining partial hold, lifting the pause on a phase 1/2 leukemia study and giving the green light to the phase 2 dose.

Gabrielle Masson Jul 6, 2023 11:33am

Curis cuts staff as pending data hint at FDA application

Nov 10, 2022 6:15am

FDA lets Curis resume enrollment for phase 1/2 leukemia study

Aug 31, 2022 7:50am

FDA lifts clinical hold on Curis' phase 1/2 lymphoma trial

Aug 18, 2022 11:23am

FDA puts Curis' leukemia trial on partial hold after death

Apr 4, 2022 8:01am

Targeting a new immune checkpoint in cancer, autoimmunity

Jan 16, 2020 2:00pm